Replies to post #213943 on Biotech Values

[DewDiligence]

NVS acquires AAAP for $82/ADS—a 44% premium to AAAP’s Nasdaq closing price on 9/27/17 (the day before it was reported that NVS might buying the company):

https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications

AAAP has an approved radiotherapy called Lutathera for rare GI and pancreatic cancers.

The nominal deal value is $3.9B. NVS plans to initiate a tender offer and will complete the buyout if ≥80% of AAAP shares are tendered.